Journal of Drugs in Dermatology Publishes Study Showcasing Clinical Improvements with Burt’s Bees’ Sensitive Skin Regimen as Adjunct to Rosacea Prescription Therapy
Data Demonstrating Regimen’s Outperformance of a Dermatologist-Recommended Control to be presented at American Academy of Dermatology Annual Meeting
DURHAM, N.C.–(BUSINESS WIRE)–Burt’s Bees, a leading provider of personal care products committed to natural health and beauty solutions, today announced that the Journal of Drugs in Dermatology has published clinical data supporting the efficacy and tolerability of Burt’s Bees skin care products as an adjunct to rosacea prescription therapy. Abstracts outlining the study data will be shared at the American Academy of Dermatology Annual Meeting on March 1-5, 2019, in Washington, D.C.
For access to the manuscript click here.
Click here to read the complete press release.